Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-11T21:22:27.688Z Has data issue: false hasContentIssue false
  • English
  • Français

Combinación de venlafaxina y clomipramina

Published online by Cambridge University Press:  12 May 2020

F. Benazzi
F. Benazzi*
Affiliation:
División de Psiquiatría, Hospital Público “Morgagni”, Forli, Italia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Cartas al editor
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 8 , November 1997 , pp. 560 - 562
Copyright
Copyright © European Psychiatric Association 1997

References

Bibliografía

Baldessarini, RJ. Drugs and the treatment of psychiatric disorders. In: Hardman, JGLimbird, LE, Molinoff, PB, Ruddon, RW, Goodman Gillman, A, eds. Goodman & Gilman ‘s. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996; 399-459.Google Scholar
Benazzi, F. Urinary retention with venlafaxine - haloperidol combination. Phamacopsychiatry, in press.Google Scholar
Benazzi, F, Venlafaxine - fluoxetine - nortriptyline interaction. Submitted for publication, a.Google Scholar
Benazzi, F, Anticholinergic toxic syndrome with venlafaxine - desipramine combination. Submitted for publication, b. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Cin Psychopharmacol 1996; 16 (suppl 2): 37S-53S.Google Scholar
Nemeroff, CB, Lindsay De Vane C, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 11-20.CrossRefGoogle Scholar
Physician's Desk Reference, 50 edition. Montvale, NJ: Medical Economics Company, 1996: 2719-23.Google Scholar
Preskorn, SH. Pharmacokinetics of antidepressant: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 (suppl 9): 14-34.Google ScholarPubMed
Preskorn, SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiatry 1996; 57 (suppl 1): 13-16.Google ScholarPubMed